BRCA1 and neoplasm: In conclusion, the adoption of BRCA1/2 tumor testing will reduce the time and cost required to identify OC patients who could benefit from PARPi therapy, but critical aspects affecting the reported results are yet to be fully understood by the community, so that they may be managed to improve overall outcomes.